Ophthalmology Times Europe E-News:
Having trouble viewing this e-mail? Click here.
You are subscribed to Ophthalmology Times Europe.
Ophthalmology Times Europe E-News
Modern Medicine Network
 
 
 
 
In this issue
Strategic ophthalmic alliance
Loteprednol etabonate controls IOP
ICG-enhanced TTT
Beclomethasone and IOP
 
 
Survey

Would you use Indocyanine green (ICG) enhanced transpupillary thermotherapy (TTT) in combination with ophthalmic artery chemosurgery to treat retinoblastoma?

Click here to vote

You can now follow us on Twitter:
www.twitter.com/oteurope

Contact Us
Click here to contact Felicity Thomas, editor.


February 20, 2013
Strategic alliance for clinical research announced
Research Dynamics Consulting Group and ClinROC LLC have announced a strategic alliance to provide clinical research and product development services for the ophthalmic industry. More...
Loteprednol etabonate controls inflammation and IOP
Loteprednol etabonate controls inflammation and reduces IOP fluctuation after cataract surgery, according to a recent study. More...
ICG-enhanced TTT effectively treats retinoblastoma
Indocyanine green (ICG) enhanced transpupillary thermotherapy (TTT) in combination with ophthalmic artery chemosurgery can effectively treat retinoblastoma refractory without ocular side effects, claims a study. More...
Beclomethasone nasal spray doesn't increase IOP
Beclomethasone nasal spray doesn't increase IOP in patients with ocular hypertension and primary open-angle glaucoma, reveals a study in the Journal of Glaucoma. More...